Antiretroviral combination therapy markedly reduces risk of heterosexual HIV-1 transmission
- 1Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
- 2Department of Medicine and Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA
- Correspondence to Eric S Rosenberg
Department of Medicine and Pathology, Massachusetts General Hospital, Gray J-504, 55 Fruit Street, Boston, MA 02114, USA;
The reduction of HIV-1 transmission remains one of the highest global health priorities. The use of established antiretroviral drugs for preventing HIV-1 transmission was first considered in 1994, after an observational clinical study showed reduced HIV-1 infection rates in partners of HIV-1 infected persons treated with zidovudine monotherapy.1 In 2007, the HIV Prevention Trials Network (HPTN) initiated a randomised-controlled clinical trial (HPTN 052) in which the effect of antiretroviral combination therapy on heterosexual transmission of HIV-1 was evaluated; the results have recently been reported.
HPTN 052 is a phase III, randomised-controlled clinical trial designed to determine if early initiation of antiretroviral therapy could reduce transmission of HIV-1 in …